AI and Safety: Finding the Signals that Matter

Moving towards the development of mature quality management systems.

Final guidance suggests sponsors select two doses for Phase II trials with additional data requirements.

Session provides insight as to how to boost interoperability and expand the middleware on a global scale.

Panel discusses the advantages that these models can provide in adding efficiencies to the clinical trial process.

According to the session panelists, tackling challenges and finding efficiencies is imperative for success.

The presentation expresses the importance of putting the patient at the center of patient recruitment.